PP405 Wakes Dormant Hair Follicle Stem Cells to Treat Hair Loss
Hair loss treatment is entering a new phase. A biotech company called Pelage Pharmaceuticals has developed a topical compound called PP405 that takes a fundamentally different approach from everything currently on the market. Rather than adjusting blood flow or suppressing hormones, it targets the metabolic state of the stem cells that generate hair in the first place.
Where hair loss actually begins
Hair grows inside structures called follicles. Follicles cycle through phases of growth, regression, and rest. Hair loss does not mean follicles have disappeared. In many cases, it means the stem cells inside the follicle are no longer activating. They remain present but dormant, unable to receive or respond to the signals that would trigger a new growth cycle.
PP405 was designed specifically for this problem. Its target is hair follicle stem cells (HFSCs) that have fallen into extended dormancy, and its goal is to bring them back online.
How PP405 works: LDH and lactate metabolism
Activating hair follicle stem cells requires a specific metabolic environment. HFSCs rely on glycolysis, a process that breaks down glucose without oxygen, and this process produces lactate as a byproduct. That lactate is not waste. It functions as a signaling molecule that helps switch stem cells into an active state.
PP405 modulates lactate dehydrogenase (LDH), the key enzyme in lactate production. By adjusting LDH activity, the compound promotes the metabolic conditions that allow dormant stem cells to reactivate, which in turn restimulates follicle function and hair growth.
This is structurally different from existing treatments. Minoxidil increases blood flow around follicles. Finasteride blocks systemic DHT (a hormone linked to follicle shrinkage). Clascoterone blocks androgen receptors locally. All three address the environment around the follicle or the hormonal signals acting on it. PP405 works inside the stem cell itself.
Phase 1b/2a clinical results
Clinical data from Phase 1b/2a trials was published in 2025.
Key numbers:
- 12.3% increase in hair counts from baseline
- 83% of participants experienced a positive hair growth response
- Topical, non-invasive application with no systemic side effects reported
An 83% response rate is notably high for alopecia trials. Existing treatments show variable efficacy across individuals, and some patients discontinue due to side effects. The breadth of response in PP405’s early trials is one of its more striking findings.
How PP405 compares to existing treatments
| Treatment | Mechanism | Target | Key Limitation |
|---|---|---|---|
| Minoxidil | Increases blood flow | Follicle environment | Effects reverse on discontinuation |
| Finasteride | Systemic DHT suppression | Hormone pathway | Sexual side effects, not for women |
| Clascoterone | Local androgen receptor blockade | Hormone pathway | Limited long-term efficacy data |
| PP405 | LDH modulation, HFSC metabolic activation | Stem cells directly | Phase 3 pending |
Because PP405 acts through a different pathway than all current treatments, researchers expect it could be combined with existing therapies for additive or synergistic effects. The mechanisms do not overlap, which means co-administration is theoretically complementary.
Designed for all genders and hair types
PP405 does not touch the hormonal axis, which removes one of the main gender-related barriers in hair loss treatment. Finasteride is contraindicated for women. Minoxidil formulations differ by gender due to concentration and side effect profiles. PP405 was designed from the outset to be applicable across genders and hair types, with a topical delivery format that limits systemic exposure.
Researchers have noted its potential relevance for female pattern hair loss, male pattern hair loss, and telogen effluvium (the kind triggered by stress, illness, or nutritional deficiency), though specific data by type will require further trials.
What comes next
Phase 3 trials are planned for 2026. The expanded study will determine trial size, follow-up duration, demographic inclusion, and dosing protocols. Regulatory approval remains at least two to three years away, but the mechanism has now cleared a critical early threshold. A compound that activates dormant follicle stem cells through metabolic signaling has produced statistically meaningful hair growth in a controlled clinical setting.
The follicles are still there. PP405 is the clearest evidence yet that the right signal can wake them up.
Frequently Asked Questions
How is PP405 different from existing hair loss treatments?
Existing treatments like minoxidil and finasteride work by increasing blood flow or blocking hormone pathways. PP405 modulates the metabolism of hair follicle stem cells directly, reactivating them from dormancy. It is the first approach to target the root cause of hair loss at the stem cell level.
Is PP405 suitable for women?
Yes. PP405 is designed to be non-invasive and suitable for all genders and hair types. However, gender-specific clinical data has not yet been published, and whether women will be included in Phase 3 trials is still being determined.
When will PP405 be available?
Phase 2a results were published in 2025, and Phase 3 trials are planned for 2026. Regulatory approval would require at least two to three additional years.